. 2019 Feb 21;5(4):491–496. doi: 10.1001/jamaoncol.2018.7086

Table. Base Case Results.

Results	Nivolumab Plus Ipilimumab	Sunitinib	ICER
Life-years	3.994	2.725	1.27
QALYs	2.842	1.882	0.96
Total cost of regimen, $	350 646	246 573	104 072
ICER, $
Per life-year			82 035 (38 665 to 234 641)^a
Per QALY			108 363 (47 452 to 286 275)^a

Abbreviations: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.

^{^a}

Values in the parentheses represent 95% credible intervals derived from the results of probabilistic sensitivity analyses.